Document Detail


Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
MedLine Citation:
PMID:  22458575     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dabigatran etexilate is a direct thrombin inhibitor that has been in clinical use for the prevention and treatment of venous and arterial thrombosis. Dabigatran allows for oral administration, has a rapid onset of action and has a predictable anticoagulant effect. Studies in healthy volunteers and in patients undergoing orthopedic surgery indicate that dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. Dabigatran is approved in the EU and Canada for prophylaxis of thromboembolism in patients undergoing total hip and knee arthroplasties. The focus of this article is on the clinical data of using dabigatran as venous thromboprophylaxis in orthopedic surgery patients.
Authors:
Reed Garza; Michael H Huo
Related Documents :
16290895 - Using qualitative evaluation in a feasibility study to improve and refine a complementa...
4015375 - Review of gunshot wounds in dayton, ohio. demographics, anatomic areas, results, and co...
20002765 - Impact of medicare part d on medicare-medicaid dual-eligible beneficiaries' prescriptio...
15260515 - Cost effectiveness of memantine in alzheimer's disease: an analysis based on a probabil...
1792875 - Results and complications of the lcs (low contact stress) knee system.
24520045 - Indications for portal vein embolization in perihilar cholangiocarcinoma.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  2012-07-31     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  423-7     Citation Subset:  IM    
Affiliation:
Department of Orthopedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antithrombins / administration & dosage*,  adverse effects,  pharmacokinetics
Benzimidazoles / administration & dosage*,  adverse effects,  pharmacokinetics
Canada
Clinical Trials as Topic
European Union
Humans
Orthopedics*
Pyridines / administration & dosage*,  adverse effects,  pharmacokinetics
Treatment Outcome
Venous Thromboembolism / prevention & control*
Chemical
Reg. No./Substance:
0/Antithrombins; 0/Benzimidazoles; 0/Pyridines; 2E18WX195X/dabigatran etexilate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZ...
Next Document:  No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-elut...